Titre | A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy |
Protocole ID | JAVELIN Bladder Medley (MS100070-0119) |
ClinicalTrials.gov ID | NCT05327530 |
Type(s) de cancer | Vessie/urothélial |
Phase | Phase II |
Stade | Maladie avancée ou métastatique |
Type étude | Clinique |
Médicament | Avélumab versus avélumab + sacituzumab govitecan versus avélumab + M6223 versus avélumab + NKTR-255 |
Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Ville | Montréal |
Investigateur(trice) principal(e) |
Dr Normand Blais |
Coordonnateur(trice) |
Chantal Gosselin 514-890-8000 poste 24892 |
Statut | Actif en recrutement |
Date d'activation | 13-01-2023 |
Critètes d'éligibilité |
Les plus pertinents
|
Critètes d'exclusion |
Les plus pertinents
|